Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PNMT | P11086 | 2/20 | 0.51 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.46 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.46 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.46 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.42 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5568961 | 1.00 | PNMT (0.51) | PNMTOPRM1OPRL1KCNH2CHRNB4 | |
| SCHEMBL14102444 | 0.85 | PNMT (0.55) | PNMTOPRM1OPRL1KCNH2 | |
| SCHEMBL3130633 | 0.76 | PNMT (0.55) | PNMTOPRM1OPRL1KCNH2 | |
| SCHEMBL16889040 | 0.74 | LTA4H (0.40) | PNMTOPRM1OPRL1KCNH2 | |
| SCHEMBL9241941 | 0.73 | CHRNB4 (0.70) | CHRNB4CHRNA3 | |
| SCHEMBL4664872 | 0.73 | CHRNB4 (0.70) | CHRNB4CHRNA3 | |
| SCHEMBL9241944 | 0.73 | CHRNB4 (0.70) | CHRNB4CHRNA3 | |
| SCHEMBL16879115 | 0.73 | PNMT (0.48) | PNMT | |
| SCHEMBL16879112 | 0.73 | PNMT (0.48) | PNMT | |
| Hydrochloric Acid SCHEMBL9244609 | 0.72 | CHRNB4 (0.68) | CHRNB4CHRNA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070265301-A1 | Dpp-IV Inhibitors | SANTHERA PHARMACEUTICALS (SCHWEIZ) AG (CH) | 2007-11-15 | — | — | US | disclosed |
| US-20070265301-A1 | Dpp-IV Inhibitors | SANTHERA PHARMACEUTICALS (SCHWEIZ) AG (CH) | 2007-11-15 | — | — | US | disclosed |
| US-20070265301-A1 | Dpp-IV Inhibitors | SANTHERA PHARMACEUTICALS (SCHWEIZ) AG (CH) | 2007-11-15 | — | — | US | disclosed |
| EP-1828138-A1 | DPP-IV INHIBITORS | Santhera Pharmaceuticals (Schweiz) AG (CH) | 2007-09-05 | — | — | EP | disclosed |
| WO-2005113510-A1 | DPP-IV INHIBITORS | SANTHERA PHARMACEUTICALS (SCHWEIZ) AG (CH) | 2005-12-01 | — | — | WO | disclosed |
| WO-2005113510-A1 | DPP-IV INHIBITORS | SANTHERA PHARMACEUTICALS (SCHWEIZ) AG (CH) | 2005-12-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070265301-A1 | Dpp-IV Inhibitors | DPP4, DPP8, DPP7 | PNMT 1660/4885OPRM1 1256/4885OPRL1 1177/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.